Caribou Biosciences, Inc. (CRBU) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
CRBU currently has 95.9M outstanding shares. with significant dilution risk as 149M authorized shares could dilute existing holders by 155.0%. The company has minimally diluted shareholders by 6.52% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 95.9M shares outstanding |
96M | 150M |
| Nov 12, 2025 |
10-Q filing | 93.3M shares outstanding |
93M | 150M |
| Aug 12, 2025 |
10-Q filing | 93.0M shares outstanding |
93M | 150M |
| May 08, 2025 |
10-Q filing | 92.7M shares outstanding |
93M | 150M |
| May 08, 2025 |
S-3 filing: Caribou Biosciences, Inc. files an S-3 registration statement to offer common stock, preferred stock, and debt securities, with a total aggregate offering price not to exceed $300,000,000; additionally offering shares of common stock having an aggregate offering price of up to $100,000,000 through an at the market offering. |
93M | 150M |
| Mar 10, 2025 |
10-K filing | 90.3M shares outstanding |
90M | 17M |
| Nov 06, 2024 |
10-Q filing | 90.5M shares outstanding |
90M | 17M |
| Aug 06, 2024 |
10-Q filing | 90.3M shares outstanding |
90M | 17M |
| May 07, 2024 |
10-Q filing | 89.3M shares outstanding |
89M | 17M |
| Mar 11, 2024 |
10-K filing | 90.3M shares outstanding |
90M | 17M |
| Nov 07, 2023 |
10-Q filing | 83.8M shares outstanding |
84M | 17M |
| Aug 08, 2023 |
10-Q filing | 88.3M shares outstanding |
88M | 17M |
| Jul 17, 2023 |
8-K filing: Caribou Biosciences, Inc. completed an offering of 19,230,769 shares of common stock at a price of $6.50 per share, resulting in expected net proceeds of approximately $116.9 million. ($125.0M proceeds) |
61M | 17M |
| Jul 06, 2023 |
8-K filing: Caribou Biosciences, Inc. completed a private placement with Pfizer Inc., issuing and selling 4,690,431 shares of common stock at $5.33 per share, resulting in gross proceeds of approximately $25 million. ($25.0M proceeds) |
61M | 17M |
| May 09, 2023 |
10-Q filing | 61.2M shares outstanding |
61M | 17M |
| Mar 09, 2023 |
10-K filing | 60.8M shares outstanding |
61M | 17M |
| Nov 08, 2022 |
10-Q filing | 60.9M shares outstanding |
61M | 17M |
| Aug 09, 2022 |
S-3 filing: The company is filing an S-3 to offer common stock, preferred stock, and debt securities with an aggregate offering price not to exceed $400,000,000. Also offering common stock through Jefferies as agent for up to $100,000,000. |
61M | 17M |
| Aug 09, 2022 |
10-Q filing | 60.8M shares outstanding |
61M | 17M |
| May 09, 2022 |
10-Q filing | 60.7M shares outstanding |
61M | 17M |
| Mar 21, 2022 |
10-K filing | 60.7M shares outstanding |
61M | 17M |
| Nov 09, 2021 |
10-Q filing | 60.2M shares outstanding |
60M | 17M |
| Sep 02, 2021 |
10-Q filing | 60.0M shares outstanding |
60M | 17M |
| Jul 22, 2021 |
S-1/A filing: Caribou Bioscience, Inc. is offering 17,000,000 shares of its common stock in an initial public offering, with an expected price between $14.00 and $16.00 per share. |
N/A | 17M |
| Jul 19, 2021 |
S-1/A filing: Caribou Bioscience, Inc. is offering 13,500,000 shares of its common stock in an initial public offering, with an expected price range of $14.00 to $16.00 per share. |
N/A | 14M |
| Jul 01, 2021 |
S-1 filing: Caribou Bioscience, Inc. is offering common stock in an initial public offering. The expected public offering price is between a specified range. The shares are expected to trade on the Nasdaq Global Select Market under the symbol CRBU. |
N/A | 0 |